TheraRadar
Data updated: Jun 28, 2026

FELODIPINE · GLENMARK PHARMS LTD

Generic · see PLENDIL Calcium Channel Antagonists
Cardiovascular Approved 1991-07-25

Felodipine extended-release tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine.

Source: FDA Label
NDA
Small Molecule
13
Indications
--
Phase 3 Trials
34
Years on Market

Details

Status
Prescription
First Approved
1991-07-25
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

FELODIPINE Approval History

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
66 FDA actions from 2004 to 2024
Dec 2024 SUPPL
Mfg · Manufacturing (CMC)
Apr 2019 ORIGINAL
Update
Oct 2018 ORIGINAL
Update

What FELODIPINE Treats

1 indications

FELODIPINE is approved for 1 conditions since its original approval in 2004. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

FELODIPINE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to FELODIPINE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACEBUTOLOL HYDROCHLORIDE
ACEBUTOLOL HYDROCHLORIDE
1 shared
ANI PHARMS
Shared indications:
ALDACTONE
SPIRONOLACTONE
1 shared
Pfizer
Shared indications:
ALISKIREN HEMIFUMARATE
ALISKIREN HEMIFUMARATE
1 shared
PH HEALTH
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT02232269 R-11-655 NA-7122 Ph 1 completed Coffee Interaction With the Antihypertensive Drug Felodipine
NCT02744872 CARCATS 2008-004771-22 Ph 4 completed Copenhagen Acute Renal Complications After Transplantations Study Group
NCT00905333 D2452L00021 IMPACT 15381 Ph 1 completed Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FELODIPINE FDA Label Details

Indications & Usage

Felodipine extended-release tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise...

Looking for the branded version?

PLENDIL

Full clinical data, patents, trials, and competitive landscape for felodipine.

See PLENDIL

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.